- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THESEUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 21,200 | 0,00 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 | Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 60,00 | 0,00 % | Canaccord Genuity raises Palvella Therapeutics stock price target to $90 on new indication | ||
| DIANTHUS THERAPEUTICS | 29,200 | -2,01 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results | Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103... ► Artikel lesen | |
| JOUNCE THERAPEUTICS | - | - | IBM's Red Hat acquires stealth Israeli startup Jounce for $20M to bolster AI cloud stack | ||
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| TOURMALINE BIO | 47,880 | +0,06 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| SPYRE THERAPEUTICS | 16,500 | 0,00 % | IBM Introduces the Spyre Accelerator for Commercial Availability | Coming this Fall to IBM Z, LinuxONE and Power, IBM Spyre Accelerator Enables Enterprises to Scale Generative and Agentic AI Workloads
ARMONK, N.Y., Oct. 7, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen |
Das Unternehmen THESEUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THESEUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.